TAVI with the ACURATE neo2 in severe bicuspid aortic valve stenosis: the Neo2 BAV Registry


Por: Rück, A, Kim, WK, Del Sole, PA, Wagener, M, Mcinerney, A, Yacoub, MS, Hasabo, EA, Ayhan, C, Elzomor, H, Neiroukh, D, Amir, A, Saleh, N, Settergren, M, Lindler, R, Verouhis, D, Sossalla, S, Renker, M, Montorfano, M, Bellini, B, Suarez, XC, Del Olmo, VV, de Marco, F, Biroli, M, Moellmann, H, Enno, EC, Tarantini, G, Fabris, T, Ielasi, A, Costa, G, Barbanti, M, Soliman, O and Mylotte, D

Publicada: 1 ene 2025 Ahead of Print: 20 ene 2025
Resumen:
BACKGROUND: The ACURATE neo2 is a contemporary transcatheter aortic valve implantation (TAVI) system approved for the treatment of severe aortic stenosis in Europe. The ACURATE neo2 has not been evaluated in bicuspid aortic valve (BAV) stenosis. AIMS: We sought to evaluate the safety and efficacy of ACURATE neo2 in patients with BAV stenosis. METHODS: We retrospectively analysed consecutive severe BAV stenosis patients undergoing TAVI with ACURATE neo2 at 10 European centres. Imaging data from preprocedural multislice computed tomography, pre- and postprocedural echocardiography, and procedural cinefluoroscopy were evaluated by a core laboratory. Valve Academic Research Consortium 3 (VARC-3)-defined 30-day procedure safety and efficacy were the primary endpoints. Adverse events were site-reported according to VARC-3 criteria. RESULTS: Among 181 patients with BAV stenosis treated with the ACURATE neo2, the mean age was 77.5 +/- 7.2 years, 58.0% were female, and the Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) score was 2.3% (1.6-3.7%). Most procedures were transfemoral, and predilatation was performed in all cases. A second valve was required in 4 cases (2.2%). VARC-3-defined technical success was 95.6%. The primary endpoints of device success and early safety occurred in 90.6% and 82.3%, respectively. At 30 days, cardiovascular death occurred in 2.2% (N=4) and stroke in 1.6% (N=3). Core laboratory-adjudicated echocardiography reported an effective orifice area of 2.0 (1.7-2.5) cm2 and a mean transvalvular gradient of 6.5 (4.6-9.0) mmHg. Half of all cases (51.2%) had no paravalvular leak, while moderate leak occurred in 4.3%. A new permanent pacemaker was required in 11 patients (6.5%). CONCLUSIONS: The ACURATE neo2 demonstrated favourable clinical outcomes and bioprosthetic valve performance at 30 days in selected patients with severe BAV stenosis.

Filiaciones:
Rück, A:
 Karolinska Univ Hosp, Dept Cardiol, Stockholm, Sweden

Kim, WK:
 Kerckhoff Heart Ctr, Dept Cardiol, Bad Nauheim, Germany

 Justus Liebig Univ Giessen, Dept Cardiol, Giessen, Germany

Del Sole, PA:
 Galway Univ Hosp, Newcastle Rd, Galway H91 YR71, Ireland

Wagener, M:
 Galway Univ Hosp, Newcastle Rd, Galway H91 YR71, Ireland

 Univ Hosp Basel, Univ Heart Ctr Basel, Basel, Switzerland

Mcinerney, A:
 Galway Univ Hosp, Newcastle Rd, Galway H91 YR71, Ireland

Yacoub, MS:
 Galway Univ Hosp, Newcastle Rd, Galway H91 YR71, Ireland

 Univ Galway, Dept Med, Galway, Ireland

Hasabo, EA:
 Galway Univ Hosp, Newcastle Rd, Galway H91 YR71, Ireland

 Univ Galway, Dept Med, Galway, Ireland

Ayhan, C:
 Galway Univ Hosp, Newcastle Rd, Galway H91 YR71, Ireland

 Univ Galway, Dept Med, Galway, Ireland

Elzomor, H:
 Galway Univ Hosp, Newcastle Rd, Galway H91 YR71, Ireland

 Univ Galway, Dept Med, Galway, Ireland

Neiroukh, D:
 Galway Univ Hosp, Newcastle Rd, Galway H91 YR71, Ireland

 Univ Galway, Dept Med, Galway, Ireland

Sossalla, S:
 Kerckhoff Heart Ctr, Dept Cardiol, Bad Nauheim, Germany

 Justus Liebig Univ Giessen, Dept Cardiol, Giessen, Germany

Renker, M:
 Kerckhoff Heart Ctr, Dept Cardiol, Bad Nauheim, Germany

 Justus Liebig Univ Giessen, Dept Cardiol, Giessen, Germany

Montorfano, M:
 Univ Vita Salute San Raffaele, Sch Med, Milan, Italy

 IRCCS San Raffaele Sci Inst, Intervent Cardiol Unit, Milan, Italy

Bellini, B:
 IRCCS San Raffaele Sci Inst, Intervent Cardiol Unit, Milan, Italy

Del Olmo, VV:
 Hosp Univ Germans Trias I Pujol, Dept Gynecol & Obstet, Badalona, Spain

de Marco, F:
 IRCCS, Milan, Italy

Biroli, M:
 IRCCS, Milan, Italy

Moellmann, H:
 St Johannes Hosp, D-44137 Dortmund, Germany

Enno, EC:
 St Johannes Hosp, D-44137 Dortmund, Germany

Tarantini, G:
 Univ Padua, Dept Cardiac Thorac & Vasc Sci & Publ Hlth, Padua, Italy

Fabris, T:
 Univ Padua, Dept Cardiac Thorac & Vasc Sci & Publ Hlth, Padua, Italy

Ielasi, A:
 IRCCS Osped Galeazzi St Ambrogio, Milan, Italy

Costa, G:
 Univ Enna Kore, Umberto I Hosp, Enna, Italy

Barbanti, M:
 DIEEI Univ Catania Italy, AOU Policlin G Rodolico San Marco, Catania, Italy

Soliman, O:
 Galway Univ Hosp, Newcastle Rd, Galway H91 YR71, Ireland

 Univ Galway, Dept Med, Galway, Ireland

Mylotte, D:
 Galway Univ Hosp, Newcastle Rd, Galway H91 YR71, Ireland
ISSN: 1774024X





EuroIntervention
Editorial
Europa Ed, 19 ALLEES JEAN JAURES B P 61508, TOULOUSE CEDEX 6, 31015, FRANCE, Francia
Tipo de documento: Article
Volumen: 21 Número: 2
Páginas: 130-139
WOS Id: 001460463200005
ID de PubMed: 39582342
imagen Green Submitted

MÉTRICAS